Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis

The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have shown promising therapeutic efficacy in nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor- (EGFR-) activating mutation. However, the inevitable recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Xiao-Hong, Xu, Zhen-Ye, Gong, Ya-Bin, Wang, Li-fang, Wang, Zhong-Qi, Xu, Ling, Cao, Fei, Liao, Ming-juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603503/
https://www.ncbi.nlm.nih.gov/pubmed/23533466
http://dx.doi.org/10.1155/2013/243859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603503/
https://www.ncbi.nlm.nih.gov/pubmed/23533466
http://dx.doi.org/10.1155/2013/243859

Ejemplares similares